TOP1 Priority: Advancing Biomarker-Driven Patient Selection for the Use of ADCs
William R Gwin1,2, Sara A Hurvitz1,2
1Division of Hematology/Oncology, Department of Medicine, University of Washington, Seattle, Washington.
Abstract:
A recent study reports the emergence of TOP1 mutations as a potential mechanism of resistance to topoisomerase inhibitor antibody-drug conjugates (ADC) in advanced breast cancer. This is a crucial first step in identifying biomarkers to guide ADC therapy selection and underscores the need for caution when sequencing ADCs with similar payloads. See related article by Abelman et al., p. 1966.
